tetano
Editor, Senior Moderator
Cureus
. 2021 Sep 13;13(9):e17942.
doi: 10.7759/cureus.17942. eCollection 2021 Sep.
Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman
Mai Fujita[SUP] 1 [/SUP], Hiroshi Ureshino[SUP] 1 [/SUP], Ayano Sugihara[SUP] 1 [/SUP], Atsujiro Nishioka[SUP] 2 [/SUP], Shinya Kimura[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is one of the greatest health concerns worldwide. Safe and effective COVID-19 vaccines are urgently needed and have been rapidly approved. COVID-19 vaccine-induced thrombocytopenia was reported as a rare adverse effect in the Vaccine Adverse Events Reporting System. A 25-year-old woman, who was previously diagnosed with immune thrombocytopenia (ITP, stage I), had exacerbated severe thrombocytopenia (platelet count of 6,000/μL) with a headache, joint pain, general fatigue, and bleeding tendency three days after receiving her second dose of the Pfizer BioNTech COVID-19 vaccine. Pulsed high-dose dexamethasone therapy rapidly ameliorated the ITP. Although it is difficult to confirm a causal association between Pfizer BioNTech COVID-19 vaccination and ITP exacerbation, abrupt onset of ITP exacerbation after vaccination suggests that the ITP may be vaccination-induced thrombocytopenia exacerbation. Rare but severe adverse events such as ITP may be observed, depending on increased numbers of individuals who receive COVID-19 vaccines worldwide. Further investigation is needed to clarify the mechanisms of COVID-19 vaccine-induced ITP.
Keywords: high-dose dexamethasone; immune-mediated thrombocytopenia; pfizer biontech covid-19 vaccine; sars-cov2; young woman.
. 2021 Sep 13;13(9):e17942.
doi: 10.7759/cureus.17942. eCollection 2021 Sep.
Immune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman
Mai Fujita[SUP] 1 [/SUP], Hiroshi Ureshino[SUP] 1 [/SUP], Ayano Sugihara[SUP] 1 [/SUP], Atsujiro Nishioka[SUP] 2 [/SUP], Shinya Kimura[SUP] 1 [/SUP]
Affiliations
- PMID: 34660131
- PMCID: PMC8513936
- DOI: 10.7759/cureus.17942
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is one of the greatest health concerns worldwide. Safe and effective COVID-19 vaccines are urgently needed and have been rapidly approved. COVID-19 vaccine-induced thrombocytopenia was reported as a rare adverse effect in the Vaccine Adverse Events Reporting System. A 25-year-old woman, who was previously diagnosed with immune thrombocytopenia (ITP, stage I), had exacerbated severe thrombocytopenia (platelet count of 6,000/μL) with a headache, joint pain, general fatigue, and bleeding tendency three days after receiving her second dose of the Pfizer BioNTech COVID-19 vaccine. Pulsed high-dose dexamethasone therapy rapidly ameliorated the ITP. Although it is difficult to confirm a causal association between Pfizer BioNTech COVID-19 vaccination and ITP exacerbation, abrupt onset of ITP exacerbation after vaccination suggests that the ITP may be vaccination-induced thrombocytopenia exacerbation. Rare but severe adverse events such as ITP may be observed, depending on increased numbers of individuals who receive COVID-19 vaccines worldwide. Further investigation is needed to clarify the mechanisms of COVID-19 vaccine-induced ITP.
Keywords: high-dose dexamethasone; immune-mediated thrombocytopenia; pfizer biontech covid-19 vaccine; sars-cov2; young woman.